Based on the responses thus far, transparency, bias, and privacy seem to be the three most critical and identified ethical challenges for using AI. I want to expand a bit on the accountability aspect, which becomes increasingly complex as AI…   Read more»

Virtual trials and telemedicine have certainly bolstered the inclusivity of recruitment, but another promising development is the use of real-world data (RWD) and artificial intelligence (AI) to select subjects more efficiently. There are CROs who are now increasingly partnering with…   Read more»

I agree that patient safety and data integrity are critical to ethical clinical research, and the principles of ICH-GCP certainly operationalize such goals. For example, ICH E6 (R2) emphasizes accurate documentation along with risk-based quality management systems, enabling sponsors and…   Read more»

Zoom is a company experiencing rapid growth due to its optimization of telehealth and virtual care. Despite Zoom being originally a video conference platform, Zoom now holds 36% of the US national telehealth market, with the industry projected to grow…   Read more»

AI can certainly transform medical device marketing, particularly when it comes to understanding audience behavior and personalizing outreach. However, I think the real issue is striking a balance between the autonomy it should have in shaping medical communications and oversight. …   Read more»

I certainly agree that patient perspectives greatly add value to marketing strategies, particularly as patients are increasingly seen as partners in their own care. However, I also think it’s essential to consider how this shift could lead to a change…   Read more»

I definitely agree that it’s unethical for companies to withhold medical devices purely for profit margins; however, I think the issue is more systemic than simply due to corporate greed. The high margins we typically see in the medical device…   Read more»

Going private can definitely liberate a company like EA from short-term shareholders’ expectations, however, I think it also has great potential to inspire greater innovation. Typically, when companies remain public, innovation is focused on incremental, market-safe improvements to drive steady…   Read more»

If I were starting my own business, I would choose to establish a Limited Liability Company (LLC), as LLCs offer both limited liability protection and simplicity in management. The protection alone of personal assets during business is an enticing factor…   Read more»

I do agree with the emphasis on the balance between QA and QC, but I would like to integrate the discussion of cost and efficiency into the balance. If QA is done well, this would reduce the number of failures…   Read more»

@krp67 I found your internship experience at Paramount Metal Finishings quite interesting, particularly the portion where you discuss how QC investigated whether rust issues were caused by drying, humidity exposure, or chemical balance. The reason I found this quite interesting…   Read more»

As embedded software is now a critical component of medical devices (e.g., insulin pumps and pacemakers), I have found that quality assurance processes extend beyond just functionality to encompass patient safety and regulatory compliance. Looking specifically at IEC 62304 (targeted…   Read more»

Something I would like to introduce to the discussion is the complexity of post-market surveillance and regulation for combination products. Contrasting standalone products (e.g., devices/drugs), combination products have unique challenges for regulation, especially if one component (e.g., biologics) is working…   Read more»

Another important point of delineation lies in the fact that clinical trials for medical devices often incorporate a higher degree of iterative design than for pharmaceuticals. Pharmaceuticals or drugs are often times developed via in-vitro testing for years before beginning…   Read more»

These are all great posts covering the various facets of regulation. One point that has not been raised is the contrast of regulation between the United States and countries outside the US. The FDA is in charge of regulating the…   Read more»

I agree that it is critical to choose a model that offers translatability to ensure therapies/devices being tested will actually be safe in humans. However, I would like to bring up the ethical standpoint. While conducting studies, both investigational research…   Read more»

A topic that has not been addressed yet is how risk tolerance influences academic and industrial regulation. Typically, industries have faced stringent regulation and oversight, as pre-clinical studies were ultimately designed with the goal of FDA approval and integration in…   Read more»

The responses thus far have already encompassed the feelings of guilt and potential reputational impacts, in addition to financial consequences when research is not finished. However, there is another aspect I would like to add, and that is the effect…   Read more»

Variance can definitely be a problem of poor estimation, but it can also reflect the health of a project in terms of its human and organizational aspects. If there are consistent schedule variances early on in a project, it may…   Read more»

I think the stakeholder groups brought up thus far are all legitimate options; however, a stakeholder group that is often overlooked in these discussions is regulators and healthcare providers. If a medical device project takes off and becomes abundantly successful,…   Read more»